Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 25,405

Document Document Title
WO/2018/043476A1
Provided is a therapeutic agent for amyotrophic lateral sclerosis, comprising: a compound represented by formula (1) (in formula (1), R1 each independently represents an alkyl group containing 1-6 carbon atoms or a 4-hydroxyphenethyl gro...  
WO/2018/038265A1
The present invention provides: a novel use of a specific bicyclic nitrogenated heterocyclic compound as a PDE7 inhibitor; a novel bicyclic nitrogenated heterocyclic compound having a PDE7 inhibition activity, a method for producing the ...  
WO/2018/038255A1
The purpose of the present invention is to provide crystals of a compound that exhibits an analgesic action against neuropathic pain and/or fibromyalgia, the crystals being useful as pharmaceuticals. The present invention provides crysta...  
WO/2018/038966A1
The present invention provides a pharmaceutical composition comprising a formulation of a corticosteroid and at least one organic acid and, optionally, a fast-acting insulin analog, in a vehicle. Also provided are methods to induce the p...  
WO/2018/034334A1
Provided is a therapeutic agent which effectively acts on diseases associated with abnormalities in dystroglycan sugar chain modification. A method for diagnosing diseases associated with abnormalities in dystroglycan sugar chain modific...  
WO/2018/030432A1
Provided is a peptide having a short chain length, e.g. 20 amino acid residues or fewer, and exhibiting high myostatin inhibitory activity. The present invention is a peptide comprising an amino acid sequence represented by formula (1) i...  
WO/2018/019244A1
The present invention relates to salts of 2,6-dimethylpyrimidone derivative and uses of the salts. The present invention also relates to a pharmaceutical composition comprising the salts or a combination thereof, and uses of the salts or...  
WO/2018/017726A1
Disclosed herein are methods and compositions for alleviating side effects of statin administration, such as myopathic or myalgic side effects, short-term memory loss, abnormal liver function, glucose intolerance, hyperglycemia, increase...  
WO/2018/012582A1
Provided is a blood amino acid level elevation promoter which contains a whey protein hydrolysate as an active ingredient. The elevation of a blood amino acid level in a subject can be promoted by feeding the promoter to the subject.  
WO/2018/010965A1
Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related m...  
WO/2018/013477A1
This document provides methods and materials for activating muscle remodeling. For example, methods and materials for using GAR1 inhibitors to activate muscle remodeling are provided.  
WO/2018/012004A1
[Problem] The purpose is to provide a "functional agent having a dynapenia-suppressing function" having as an active ingredient components isolated and obtained from leaves or flowers of a specific plant raw material by a specific method...  
WO/2018/007475A1
The current invention provides antisense splice-switching oligonucleotides with improved characteristics that enhance clinical applicability for treating, ameliorating, preventing, and/or delaying neuromuscular disorders, such as DMD.  
WO/2018/009544A1
The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK...  
WO/2018/009609A1
The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I. Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceut...  
WO/2018/008749A1
A nucleic acid which can inhibit expression of the MEX3B gene with low cytotoxicity as a side effect, an MEX3B gene expression inhibitor which contains said nucleic acid, a method for inhibiting MEX3B gene expression, and a prophylactic ...  
WO/2018/003962A1
2- (Piperidin-1-yl) pyrimidin-4 (3H) -ones characterized by having a 1,8-diazaspiro [4.5] deca-3-ene, 1-oxa-8-azaspiro [4.5] deca-3-ene, 2,8-diazaspiro [4.5] deca-3-ene, 2-oxa-8-azaspiro [4.5] deca-3-ene, 2,9-diazaspiro [5.5] undeca-3-en...  
WO/2018/000098A1
A method of treating an inflammatory myopathy includes topically administering to the skin of an individual with the inflammatory myopathy a composition comprising R-salbutamol, a physiologically acceptable derivative thereof, or a pharm...  
WO/2018/005805A1
Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.  
WO/2017/222040A1
The present invention provides a pharmaceutical composition which can be administered to a human body safely and is effective for the treatment of PolyQ diseases. The present invention provides: a pharmaceutical composition which contain...  
WO/2017/221883A1
[Problem] The present invention provides an antibody-drug conjugate (ADC). The present invention also provides a conjugate of an anti-CD71 antibody or an antigen-binding fragment thereof with a drug. The present invention further provide...  
WO/2017/218825A1
DNA-targeted nanocarriers for encapsulating an active agent and delivering it to extracellular DNA are provided. The nanocarriers, for example, polymeric particles, liposomes, and multilamellar vesicles have targeting moiety that targets...  
WO/2017/218592A1
The present disclosure relates to the treatment of muscle conditions, such as SMA, with the use of an agent that inhibits myostatin signaling. The disclosure includes combination therapies that include a myostatin inhibitor and a neurona...  
WO/2017/217525A1
The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The disclosure also provides ...  
WO/2017/217556A1
The purpose of the present invention is to provide a medicine for preventing or treating TGFβ-related diseases by inhibiting signal transduction of TGFβ. Provided are: a TGFβ inhibitor that contains, as an active ingredient, the REIC/...  
WO/2017/217439A1
The purpose of the invention is to provide a compound that inhibits the binding of the ALS-related mutant SOD1 and Derlin-1, a drug containing the compound, and a method for treating ALS by administering the drug to a patient. More speci...  
WO/2017/211274A1
Provided are the use of lipids bearing fatty acids with an odd number of carbon atoms as pharmaceuticals or nutritional supplement. In particular, such lipids are used in the treatment and/or prevention of neurodegenerative diseases, opt...  
WO/2017/211303A1
Provided are certain pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as...  
WO/2017/210989A1
Disclosed are a phloroglucinol-oxytocin injection and a preparation method therefor. Each 10,000 ml injection contains 100 ml of an oxytocin solution and 0.2 g of phloroglucinol, and a 1 ml injection contains 10 units of the oxytocin sol...  
WO/2017/213854A1
Provided herein are pharmaceutical compositions comprising Eteplirsen. Also provided herein are methods of treating a muscle disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of th...  
WO/2017/207678A1
Wnt-inducible signalling protein 1 (WISP1) or a fragment or variant thereof for use in maintaining or increasing muscle function and/or mass in a subject, and/or substantially preventing or reducing muscle wasting in a subject.  
WO/2017/207600A1
The present invention relates to olesoxime for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.  
WO/2017/209290A1
The present invention provides a method for producing a motor neuron from a pluripotent stem cell, said method comprising the following steps: (1) introducing a single Sendai virus vector carrying a nucleic acid encoding Lhx3, a nucleic ...  
WO/2017/201585A1
Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors...  
WO/2017/204277A1
The present invention provides an anti-TGF-beta3 antibody and a method of using the antibody. The anti-TGF-beta3 antibody according to the present invention has a binding activity to TGF-beta3 but does not have a neutralizing activity to...  
WO/2017/205101A1
The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that s...  
WO/2017/203083A1
The present invention relates to 1,2,3-triazoles of formula (I), which can be used to improve or restore intracellular calcium homeostasis and RyR-calstabin binding in human and animal cells. The invention also relates to methods for syn...  
WO/2017/199976A1
The present invention addresses the problem of providing a novel use of pluripotent stem cells (Muse cells) for medical purposes in regenerative medicine. The present invention provides a cell preparation and a pharmaceutical composition...  
WO/2017/199250A1
Isolated cells of a mixed character, possessing a mesenchymal stem cell phenotype and a muscle cell phenotype, as well as extracellular vesicles secreted from same, pharmaceutical compositions comprising same, and methods of treatment co...  
WO/2017/197328A1
Enteral Feeding Intolerance (EFI) and conditions associated with loss of muscle mass can be efficaciously treated by administration of therapeutically effective doses of relamorelin every 8 hours (three times a day). Therapeutic benefit ...  
WO/2017/197107A1
The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A2 rec...  
WO/2017/194975A1
The invention provides anelastase inhibitorfor use in the promotion of muscle regeneration in the treatment of a myopathy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providin...  
WO/2017/197131A1
Enteral feeding intolerance and conditions associated with loss of muscle mass can be efficaciously treated by administration of therapeutically effective doses of ulimorelin every 8 hours (three times a day). Ulimorelin is administered ...  
WO/2017/193563A1
A composition, and an application and pharmaceutical preparation thereof. The invention provides a plurality of novel compositions and preparations comprising a berberine in combination with EPA and DHA, and an application thereof for tr...  
WO/2017/190708A1
Provided in the present invention are a compound as represented by formula (I), a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, and a hydrate thereof or a pharmaceutically acceptable salt and ester thereof, a...  
WO/2017/187319A1
Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.  
WO/2017/181857A1
A composition for fat reduction and liver protection, a preparation method thereof, and a pharmaceutical product comprising same. The composition comprises: Radix Astragali, Radix Puerariae, and Cortex Mori. The mass ratio of Radix Astra...  
WO/2017/183028A1
The present invention provides compositions and methods for treating fibromyalgia syndrome (FMS). Specifically, the present invention provides anti eotaxin-2 antibodies for treating FMS.  
WO/2017/178856A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or limit development of neuromuscular diseases, including motor neuron diseases like amyotrophic lateral sclerosis.  
WO/2017/181014A1
The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from dystroph...  

Matches 301 - 350 out of 25,405